Avrobio (AVRO) PT Lowered to $6 at Needham & Company, "Buy" Rating Maintained, "Encouraged by Evolving ARV-RD-04 Results" May 17, 2022 10:40AM
AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference Apr 5, 2022 07:00AM
Needham & Company Reiterates Avrobio (AVRO) at Outperform, $8 PT, Remains Supporter of Company's LV Based Gene Therapy Programs Mar 17, 2022 10:14AM
Avrobio Inc. (AVRO) PT Lowered to $8 at Needham & Company Jan 4, 2022 03:08PM
Repare Therapeutics Appoints Dr. Maria Koehler as Chief Medical Officer, Katina Dorton as Chief Financial Officer and Carol Schafer to its Board of Directors May 1, 2019 08:00AM